Events

03

Mar

2018

CRT 2018: Late-breaking trial summaries

Event img
Company image

The Omni Shoreham Hotel

The CRT conference is one of the highlights of the cardiovascular education calendar. This year's CRT2018 took place on March 3-6 at the Omni Shoreham Hotel in Washington, DC. The conference featured 12 late-breaking abstracts, details of which are described below:

  1. Transcatheter Aortic Valve Replacement for Patients With Severe Aortic Stenosis Who Are At Low Risk For Mortality: Interim results From The Prospective Multicentre LRT Clinical Trial
    Ron Waksman, MD, FSCAI, Georgetown University, Washington DC.
  2. Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation: REAC TAVI trial
    Victor Jimenez Diaz, MD, University Alvaro Cunquiero, University of Vigo, Spain
  3. Debris Heterogeneity Across Different Valve Types Captured by A Cerebral Protection System During TAVR
    Tobias Schmidt, MD, Department of Cardiology, Asklepios Klinik St. Georg, Hamburg.
  4. Transcatheter Aortic Valve Replacement for The Treatment of Pure Native Aortic Valve Regurgitation
    Danny Dvir, MD, University of Washington Medical Center, Seattle
  5. High-Bleeding Risk Analysis of the BIO-RESORT Randomized Trial, Comparing 12-Month Clinical Outcome of Allcomer Patients Treated with Very Thin-Strut Biodegradable Polymer Versus Thin-strut Durable Polymer Drug-Eluting Stents
    Clemens von Birgelen, MD, PhD, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands.
  6. Impact of Crushed Ticagrelor Vs. Eptifibatide Bolus + Clopidogrel On Platelet Reactivity and Periprocedural Myocardial Infarction in Patients with Unstable Angina
    Massoud Leesar, MD, University of Birmingham, Alabama.
  7. EluNIRTM Ridaforolimus-Eluting Coronary Stent System – The BIONICS 2-Year Clinical Outcomes
    Ori Ben-Yehuda, the Cardiovascular Research Foundation, New York.
  8. LIBERTY 360 Study: 18-Month Outcomes of Endovascular Device Interventions in Patients with Symptomatic Lower Extremity Peripheral Artery Disease
    William A. Gray, MD, FSCAI, Lankenau Heart Institute, Wynnewood, PA USA.
  9. Radial Versus Femoral Access in Patients with Acute Coronary Syndromes Undergoing Invasive Management: Prespecified Subgroup Analysis from the VALIDATE-SWEDEHEART Trial
    Elmir Omerovic, MD, PhD, University of Gothenburg, Gothernburg, Sweden.
  10. A Multicenter Randomized Clinical Trial To Evaluate The Efficiency Of Small Vessel Coronary Treatment Using Paclitaxel Drug-coated Balloon Versus Zotarolimus-eluting Stent: RAMSES trial
    Victor Jimenez Diaz, MD, University Alvaro Cunquiero, University of Vigo, Spain.
  11. Impact Of Lesion Length On 6 Months Efficacy When Using A DCB. Insights From The Selution Trial: A Novel Sirolimus Coated DCB Technology Evaluated In SFA
    Thomas Zeller, MD, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany.
  12. First-in-Human Experience with the Edwards SAPIEN M3 System: A Novel Transeptal Transcatheter Mitral Valve Replacement Alternative for the Treatment of Mitral Regurgitation
    John Webb, St Paul’s Hospital, Vancouver, Canada.

Start date

End date

Company image
www.crtmeeting.org www.crtmeeting.org